Navigation Links
EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
Date:9/10/2007

n preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
7. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Pa. , Aug. 27, 2015  PinnacleHealth CardioVascular Institute ... and second in the United States ... new type of stent for blockages in the main artery ... within the artery and potentially less risk for stent fracture ... is a prospective, single-arm, multicenter clinical trial of the BioMimics ...
(Date:8/27/2015)... , Aug. 27, 2015  Lightwave Logic, ... the development of Next Generation Photonic Devices ... applications in high speed fiber-optic data communications and ... Lebby has been appointed to the Company,s ... in the field of optoelectronics is widely recognized ...
(Date:8/27/2015)... 27, 2015  CytomX Therapeutics, Inc., a biopharmaceutical ... cancer, today announced that Rachel Humphrey , ... of Directors, has been appointed chief medical officer. ... and AstraZeneca, and also oversaw clinical development of ... at Bristol-Myers Squibb and the development of Nexavar ...
Breaking Medicine Technology:First Pennsylvania Patient Treated in Landmark Vascular Study 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
... Corporation (Nasdaq: OMER ), a biopharmaceutical company ... inflammation and disorders of the central nervous system, today ... call Monday afternoon, October 25, 2010 at 4:00 p.m. ... Demopulos, M.D., chairman and chief executive officer, will provide ...
... 22 Endo Pharmaceuticals (Nasdaq: ENDP ) today announced ... Healthcare Conference on Tuesday, November 2, 2010, at 2:10 p.m. EDT. ... company,s products and development programs. There will be a ... www.endo.com under the investors section. About ...
Cached Medicine Technology:Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update 2
(Date:8/27/2015)... ... ... In an article published July 30th by the New York ... highlighting a security firm that is tasked with providing supplemental protection. Called the French ... with the city to provide private security when it is needed in a city ...
(Date:8/27/2015)... ... August 27, 2015 , ... On May 30th, 2015, at the Adams ... sponsor of the “Music With A Mission” benefit concert. For the past two years, ... in the underfunded school districts of Mendon and neighboring town, Quincy, IL. Organized in ...
(Date:8/27/2015)... ... August 27, 2015 , ... Infocast ... for October 27-29, 2015 in San Jose, CA. The first event dedicated ... on the void that exists where battery development and energy storage innovation are ...
(Date:8/27/2015)... ... August 27, 2015 , ... More destinations and stores are becoming pet-friendly, ... Amica Insurance is sharing some tips to help your whole family travel safely and ... travel with pets each year. Amica is sharing the following tips from the American ...
(Date:8/27/2015)... ... 27, 2015 , ... For the first time, Ninja® introduces ... Nutri Ninja® Auto-iQ Pro Complete and Nutri Ninja Auto-iQ Compact System. These two ... customization to a whole new level. This line of Nutri Ninja products is ...
Breaking Medicine News(10 mins):Health News:Article on New Orleans Security Force Highlights the Abilities and Flexibility of Private Security, says Spear Security Inc. 2Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 4
... an as yet unknown reason, cancer radiotherapy can increase ... problem that is growing as more and more people ... now suggests that sustained inflammation induced by post-radiotherapy changes ... the cause. Epidemiological studies have shown that ...
... historian Nicholas Everett and Walid Saleh, a scholar of ... each been selected to receive a highly competitive New ... research. It is the first time the fellowships, ... United States. The New Directions Fellowships are ...
... whites at specialized cancer centers, research shows , MONDAY, ... cancer patients receive similar care at specialized cancer centers, ... a U.S. study has found. , The finding suggests ... previous findings of racial disparities in cancer deaths, the ...
... ... ... ... MONTREAL , March 22 /PRNewswire/ - Haemacure Corporation (TSX:HAE) announces that it has obtained authorization from the Superior Court of the Province of Québec to sell ...
... available to parents and pupils about asbestos exposure in schools. The call comes less than a month after a report by the Asbestos Training and Consultancy ... ... , ... ...
... Bakeries Across USA Join Campaign For Epilepsy Awareness , ... , , ... ... NEW YORK , March 22 This week, bakeries across ...
Cached Medicine News:Health News:Radiotherapy can cause lasting vascular disease 2Health News:University of Toronto scholars receive prestigious New Directions Fellowships 2Health News:Where Cancer Treatment Takes Place May Influence Outcome 2Health News:Court Authorizes Haemacure to Sell its Assets and Grants a Second Extension to Make a Proposal to its Creditors 2Health News:First Personal Injury on Asbestos in Schools 2Health News:Purple Cupcake Production on the Rise Nationwide 2Health News:Purple Cupcake Production on the Rise Nationwide 3
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... T helps provide protection to the exposed airway ... extremely lightweight making it ideal for active young ... rate of heat and moisture recovery, it ensures ... HMEs and filters have ISO standard tapered ends ...
... The AlphaPette Pipettor is the #1 ... Offers accuracy, comfort, and reliability. Continuously ... volume readout sub-micrometer. Easy interchangeable ejector ... tiny hands. Adjustable rapid pipet tip ...
... Our variable volume Finnpipette ... in a high performance pipette. ... colour-coded volume range, ensures quality, ... identification of the volume range ...
Medicine Products: